Scutellarin inhibits the glioma cell proliferation by downregulating BIRC5 to promote cell apoptosis

Abstract

Glioma is considered as the most common primary tumour in the adult brain, with the highest degree of malignancy; among glioma types, glioblastoma is the most invasive and lethal. 1,2 Although multinational treatment strategies have improved in the past few decades, the prognosis of patients with glioma remains unfavourable. 3,4 In particular, the median survival time of patients with high-grade malignant glioma is ≤14 months. 5,6 And the 5-year survival rate of glioblastoma patients is <3%. 7 Therefore, there is an urgency to explore the mechanism of the invasiveness of glioma and to develop new therapeutic strategies, but particularly to find new anticancer drugs. Scutellarin, also known as Erigeron scutellarin, is a traditional Chinese medicine commonly found in Yunnan, Guizhou, Sichuan and other southwestern provinces. Its chemical name is 4′,5,6-trihydrox

Current advances on the therapeutic potential of scutellarin: an updated review

“…Wang et al [ 56 ] found that scutellarin was able to inhibit the growth of glioma, as well as the proliferation and migration of glioma cells. In addition, scutellarin could significantly reduce the expression of baculovirus inhibitor of apoptosis protein 5 (BIRC5), thereby reversing the inhibition of apoptosis in glioma cells and exerting its anti-glioma effect.…”